Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821567 | 1.00 | FOLH1 (0.42) | FOLH1TAS1R3TAS1R1MMEBIRC2 | |
| SCHEMBL27589188 | 1.00 | FOLH1 (0.42) | FOLH1TAS1R3TAS1R1MMEBIRC2 | |
| SCHEMBL2503547 | 0.89 | FOLH1 (0.44) | FOLH1TAS1R3TAS1R1MMEBIRC2 | |
| SCHEMBL3962360 | 0.86 | BCHE (0.49) | FOLH1TAS1R3TAS1R1BIRC2BCHE | |
| SCHEMBL3962361 | 0.86 | BCHE (0.49) | FOLH1TAS1R3TAS1R1BIRC2BCHE | |
| SCHEMBL11932570 | 0.86 | FOLH1 (0.46) | FOLH1TAS1R3TAS1R1MMEBIRC2 | |
| SCHEMBL13360911 | 0.84 | POLB (0.42) | FOLH1TAS1R3TAS1R1MMEBIRC2 | |
| SCHEMBL3956295 | 0.83 | BIRC2 (0.49) | FOLH1TAS1R3TAS1R1BIRC2BCHE | |
| SCHEMBL3957109 | 0.83 | BIRC2 (0.49) | FOLH1TAS1R3TAS1R1BIRC2BCHE | |
| SCHEMBL3957111 | 0.83 | BIRC2 (0.49) | FOLH1TAS1R3TAS1R1BIRC2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303527-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| CN-1443190-A | Matrix metalloproteinase inhibitors | LEO PHARM PROD LTD (DK) | 2003-09-17 | — | — | CN | disclosed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | disclosed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | FOLH1 1531/4885TAS1R3 2750/4885TAS1R1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.